Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Invested Capital (2016 - 2025)

Regenxbio has reported Invested Capital over the past 12 years, most recently at $102.7 million for Q4 2025.

  • Quarterly results put Invested Capital at $102.7 million for Q4 2025, down 60.43% from a year ago — trailing twelve months through Dec 2025 was $102.7 million (down 60.43% YoY), and the annual figure for FY2025 was $102.7 million, down 60.43%.
  • Invested Capital for Q4 2025 was $102.7 million at Regenxbio, down from $161.5 million in the prior quarter.
  • Over the last five years, Invested Capital for RGNX hit a ceiling of $764.3 million in Q4 2021 and a floor of $102.7 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $398.3 million (2023), compared with a mean of $414.3 million.
  • Biggest five-year swings in Invested Capital: surged 102.33% in 2021 and later tumbled 60.43% in 2025.
  • Regenxbio's Invested Capital stood at $764.3 million in 2021, then tumbled by 32.46% to $516.2 million in 2022, then tumbled by 39.61% to $311.7 million in 2023, then dropped by 16.71% to $259.7 million in 2024, then tumbled by 60.43% to $102.7 million in 2025.
  • The last three reported values for Invested Capital were $102.7 million (Q4 2025), $161.5 million (Q3 2025), and $213.7 million (Q2 2025) per Business Quant data.